Ascendis Pharma and BioMarin Settle Patent Dispute, Paving Way for Enhanced Focus on Genetic Disorder Treatments
Ascendis Pharma and BioMarin Pharmaceutical have reached a legal settlement resolving their patent disputes over treatments for a specific genetic disorder in children. Under the agreement, Ascendis has agreed to pay BioMarin royalties, thus bringing an end to ongoing proceedings at the U.S. International Trade Commission and various court venues, including California federal court. For…